EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real-World 12 and 18-Month Outcomes of Faricimab in Patients Previously Treated for Neovascular Age-Related Macular Degeneration

Tun Giap Tan, Radua Kamal-Salah, Olayinka Osoba

Journal of Clinical & Translational Ophthalmology · 2026-10-31 · 4 (4) · 27

DOI: 10.3390/jcto4040027 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Faricimab was demonstrated to be efficacious in treatment-naïve patients. We evaluated real-world outcomes of faricimab in patients with neovascular age-related macular degeneration (nAMD) who responded suboptimally to other anti-VEGF treatment or had a high treatment burden. Method: Single-centre retrospective study of nAMD patients switched to faricimab from September to December 2022 with a minimum of 12 months’ follow-up. Main outcomes included best-corrected visual acuity (BCVA), central subfield thickness (CST), and treatment intervals at 12 and 18 months. Results: A total of 71 eyes (62 patients) and 60 eyes (53 patients) with sufficient follow-up data were included in the analysis at 12 and 18 months respectively. Median BCVA decreased from 68 ETDRS letters (IQR 57–74) to 66 (IQR 55–75) at 12 months (p = 0.119) and 67 (IQR 55–73) at 18 months (p = 0.009). Median CST decreased from 296 µm (IQR 270–339) at baseline to 273 µm (245–313, p < 0.001) and 263 µm (240–300, p < 0.001) at 12 and 18 months respectively. Overall, 5.6% of eyes had a dry macula at baseline, compared to 26.8% (p = 0.002) and 31.7% (p = 0.001) at 12 and 18 months respectively. Mean treatment interval increased from 5.2 ± 1.6 weeks at baseline, to 7.4 ± 2.8 weeks (p < 0.001) at 12 months, and 7.5 ± 3.1 weeks (p < 0.001) at 18 months. One case of hypertensive anterior uveitis and one case of post-injection hypotony were reported during follow-up. Conclusions: Switching to faricimab for nAMD was associated with a decline in visual acuity that was not clinically meaningful, with the majority of eyes avoiding moderate visual loss. Anatomical outcomes improved, and treatment intervals were extended over 18 months.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →